Welcome to LookChem.com Sign In|Join Free
  • or
(+)-2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol is a complex organic compound characterized by the presence of multiple functional groups, including a triazole ring, an oxane ring, a phenyl group, and a pyridoindole ring. The chiral center, indicated by the (+) sign, suggests the existence of two enantiomeric forms. Its intricate structure, particularly the pyridoindole ring, hints at potential pharmacological applications, although further research is required to elucidate its specific biological and chemical properties.

1800340-40-2

Post Buying Request

1800340-40-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1800340-40-2 Usage

Uses

Used in Pharmaceutical Industry:
(+)-2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol is used as a potential anti-cancer agent for its possible activity against various types of cancer. The presence of the pyridoindole ring, a common structural feature in compounds with anti-cancer properties, suggests that (+)-2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol may have therapeutic potential in oncology.
Used in Chemical Research:
In the field of chemical research, (+)-2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol serves as a subject for studying the synthesis and properties of complex organic molecules. Its unique structure allows for investigations into the effects of different functional groups on chemical reactivity and stability.
Used in Drug Development:
(+)-2-[3-(dimethyl-1H-1,2,3-triazol-5-yl)-5-[oxan-4-yl(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol is utilized in drug development as a lead compound for the design of new pharmaceuticals. Its chiral nature and the presence of various functional groups provide opportunities for optimization and modification to enhance its pharmacological properties and selectivity.

Check Digit Verification of cas no

The CAS Registry Mumber 1800340-40-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,0,3,4 and 0 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1800340-40:
(9*1)+(8*8)+(7*0)+(6*0)+(5*3)+(4*4)+(3*0)+(2*4)+(1*0)=112
112 % 10 = 2
So 1800340-40-2 is a valid CAS Registry Number.

1800340-40-2Downstream Products

1800340-40-2Relevant academic research and scientific papers

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design

Ahuja, Vijay,Delucca, George,Dodd, Dharmpal,Everlof, Gerry,Gavai, Ashvinikumar V.,Gill, Patrice,Han, Wen-Ching,Harikrishnan, Lalgudi,Huang, Christine,Hunt, John T.,Huynh, Tram,Kamau, Muthoni,Lee, Francis Y.,Li, Jianqing,Li, Peng,Marsilio, Frank,Mathur, Arvind,Menard, Krista,Mussari, Christopher,Norris, Derek,O'Malley, Daniel,Poss, Michael,Quesnelle, Claude,Raghavan, Nirmala,Rampulla, Richard,Ranasinghe, Asoka,Sheriff, Steven,Sun, Dawn,Tokarski, John S.,Tortolani, David,Traeger, Sarah C.,Tye, Ching Kim,Vaccaro, Wayne,Vite, Gregory,Wee, Susan,Wen, Mei-Li,Westhouse, Richard,Wu, Dauh-Rurng,Yan, Chunhong,Yang, Zheng,Yip, Henry,Zhang, Haiying,Zhang, Huiping,Zhang, Yingru,Zhao, Yufen

, p. 14247 - 14265 (2021/10/12)

Inhibition of the bromodomain and extra-terminal (BET) family of adaptor proteins is an attractive strategy for targeting transcriptional regulation of key oncogenes, such as c-MYC. Starting with the screening hit 1, a combination of structure-activity re

NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

-

Paragraph 0347; 0348; 0435, (2016/07/27)

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

-

Page/Page column 68; 69; 103; 104, (2015/07/15)

The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1800340-40-2